SCHEMBL4522446

SCHEMBL4522446

CCOC(=O)c1cc2c(Cl)nc(Cc3ccccc3)nc2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
L3MBTL1 Q9Y468 4/20 0.47
RXFP1 Q9HBX9 3/20 0.47
PRNP P04156 2/20 0.47
KDM4E B2RXH2 5/20 0.46
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
CASP3 P42574 1/20 0.43
ATM Q13315 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
POLB P06746 1/20 0.42
TSHR P16473 2/20 0.41
HSD17B10 Q99714 1/20 0.41
PDE5A O76074 1/20 0.41
CDC7 O00311 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
DBF4 Q9UBU7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513057 0.87 SMN1; SMN2 (0.44) L3MBTL1RXFP1KDM4ESMN1; SMN2TSHR
SCHEMBL29120717 0.82 KDM4E (0.45) MAPTL3MBTL1RXFP1KDM4ENPC1
SCHEMBL28983727 0.80 KDM4E (0.43) MAPTL3MBTL1KDM4ENPC1RAB9A
SCHEMBL4531480 0.79 ALDH1A1 (0.61) MAPTL3MBTL1RXFP1PRNPKDM4E
SCHEMBL1424692 0.78 HSP90AB1 (0.47) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4907754 0.78 MAPT (0.43) MAPTL3MBTL1KDM4ENPC1RAB9A
SCHEMBL3491252 0.78 PDE5A (0.61) L3MBTL1RXFP1KDM4ENPC1RAB9A
SCHEMBL4511349 0.77 KMT2A (0.53) MAPTL3MBTL1RXFP1KDM4ENPC1
SCHEMBL28983736 0.76 MAPT (0.41) MAPTL3MBTL1KDM4ENPC1RAB9A
SCHEMBL7056137 0.76 SELE (0.48) MAPTL3MBTL1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 MAPT 1619/4885L3MBTL1 602/4885RXFP1 739/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 MAPT 1619/4885L3MBTL1 602/4885RXFP1 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.